These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29718366)

  • 1. Intratumoral heterogeneity of oxygen metabolism and neovascularization uncovers 2 survival-relevant subgroups of IDH1 wild-type glioblastoma.
    Stadlbauer A; Zimmermann M; Doerfler A; Oberndorfer S; Buchfelder M; Coras R; Kitzwögerer M; Roessler K
    Neuro Oncol; 2018 Oct; 20(11):1536-1546. PubMed ID: 29718366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic MR imaging of the tumor microenvironment revealed switching of metabolic phenotype upon recurrence of glioblastoma in humans.
    Stadlbauer A; Oberndorfer S; Zimmermann M; Renner B; Buchfelder M; Heinz G; Doerfler A; Kleindienst A; Roessler K
    J Cereb Blood Flow Metab; 2020 Mar; 40(3):528-538. PubMed ID: 30732550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
    Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results.
    Stadlbauer A; Zimmermann M; Bennani-Baiti B; Helbich TH; Baltzer P; Clauser P; Kapetas P; Bago-Horvath Z; Pinker K
    Mol Imaging Biol; 2019 Aug; 21(4):758-770. PubMed ID: 30478507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular architecture mapping for early detection of glioblastoma recurrence.
    Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
    Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Energy Metabolism in
    van Noorden CJF; Hira VVV; van Dijck AJ; Novak M; Breznik B; Molenaar RJ
    Cells; 2021 Mar; 10(3):. PubMed ID: 33810170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization.
    Wang W; Li T; Cheng Y; Li F; Qi S; Mao M; Wu J; Liu Q; Zhang X; Li X; Zhang L; Qi H; Yang L; Yang K; He Z; Ding S; Qin Z; Yang Y; Yang X; Luo C; Guo Y; Wang C; Liu X; Zhou L; Liu Y; Kong W; Miao J; Ye S; Luo M; An L; Wang L; Che L; Niu Q; Ma Q; Zhang X; Zhang Z; Hu R; Feng H; Ping YF; Bian XW; Shi Y
    Cancer Cell; 2024 May; 42(5):815-832.e12. PubMed ID: 38640932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Hatae R; Yoshimoto K; Mizoguchi M; Suzuki SO; Yoshiura T; Honda H
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):58-65. PubMed ID: 26405082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
    Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
    Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
    Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD
    Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
    Khan I; Waqas M; Shamim MS
    J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?
    Sarmiento JM; Mukherjee D; Black KL; Fan X; Hu JL; Nuno MA; Patil CG
    J Neurol Surg A Cent Eur Neurosurg; 2016 May; 77(3):195-200. PubMed ID: 26935296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effect of vascularity between long- and short-term survivors with IDH1/2 wild-type glioblastoma.
    Álvarez-Torres MDM; Fuster-García E; Reynés G; Juan-Albarracín J; Chelebian E; Oleaga L; Pineda J; Auger C; Rovira A; Emblem KE; Filice S; Mollà-Olmos E; García-Gómez JM
    NMR Biomed; 2021 Apr; 34(4):e4462. PubMed ID: 33470039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of microvascular patterns via cluster analysis reveals their prognostic significance in glioblastoma.
    Chen L; Lin ZX; Lin GS; Zhou CF; Chen YP; Wang XF; Zheng ZQ
    Hum Pathol; 2015 Jan; 46(1):120-8. PubMed ID: 25455996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
    Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
    Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.